Praxis Precision Medicines Inc
Research Praxis Precision Medicines Inc (PRAX) on Bullrun: market cap USD 10.27B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPRAX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.27B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 326.53M
- Free cash flow-USD 86.21M
Valuation Snapshot
latest market cap is USD 10.27B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 303.00M | -USD 249.12M | n/a | -13.48 | USD 357.33M | USD 110.00K | USD 878.14M |
| FY2024 | USD 8.55M | -USD 183.00M | -USD 131.76M | n/a | -10.21 | USD 215.37M | USD 1.37M | USD 445.45M |
| FY2023 | USD 2.45M | -USD 123.00M | -USD 111.19M | n/a | -18.69 | USD 81.30M | USD 2.50M | USD 69.67M |
| FY2022 | USD 0 | -USD 214.00M | -USD 185.49M | n/a | -69.65 | USD 61.62M | USD 3.96M | USD 76.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.27B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.43B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.49B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 190.94M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 112.14M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 892.41M | n/a | n/a | n/a |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Praxis Precision Medicines Inc's market cap?
Praxis Precision Medicines Inc's market capitalization is USD 10.27B.
What does Praxis Precision Medicines Inc do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.